Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive crawled date : 2021 - 09 - 28 save search
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy
Published: 2021-09-28 (Crawled : 22:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.72%
H: 2.68%
C: 2.2%
treatment fda positive therapy cancer colorectal cancer
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
Published: 2021-09-28 (Crawled : 13:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -1.41%
H: 1.27%
C: 0.74%
phase 2 positive cancer colorectal cancer trial her2+ enroll her2- her2
Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial
Published: 2021-09-28 (Crawled : 12:15) - globenewswire.com
OTLK P | $8.285 -3.78% -3.92% 230K
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: -3.08%
positive phase 3 trial
Stealth BioTherapeutics Presents Positive Elamipretide Data in Pediatric Cardiology at International Society for Heart Research North American Section Meeting 2021
Published: 2021-09-28 (Crawled : 12:00) - prnewswire.com
MITO | $0.32 0.25%
|
Health Technology
|
| O: 0.0%
H: 3.03%
C: -3.55%
heart cardiology positive research iot cardio elamipretide
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
ALT | $6.9 -1.99% -2.03% 3.2M
|
Commercial Services
|
| O: -28.7%
H: 39.15%
C: 36.75%
positive results phase 1 positive results trial obesity phase 2 phase 3
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
Published: 2021-09-28 (Crawled : 07:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.15%
H: 0.06%
C: -0.6%
phase 1 positive results vaccine phase 2 phase 3
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
Published: 2021-09-28 (Crawled : 06:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
disease phase 2 positive phase 2 results results vaccine response
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.